Esperion Therapeutics

Yahoo Finance • 5 days ago

Oritain expands traceability offer to leather

Oritain’s proprietary methodology, already trusted across apparel, food, and agriculture, can now verify the geographic origin of leather from key producing countries across Europe, Africa and South America. Oritain says this capability i... Full story

Yahoo Finance • 10 days ago

Esperion Partner Otsuka Receives Regulatory Approval to Market NEXLETOL® in Japan for the Treatment of Hypercholesterolemia

ANN ARBOR, Mich., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that Otsuka Pharmaceutical Co., Ltd. (Otsuka), the Company’s partner for the development and commercialization of NEXLETOL® (bempedoic acid) tab... Full story

Yahoo Finance • last month

Esperion’s Bempedoic Acid Receives Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidaemias

– Bempedoic Acid Receives Strongest Endorsement from ESC/EAS Guidelines Based on Compelling and Practice-Changing Evidence – – Guideline Recognition of ‘Strike Early and Strike Strong’ Approach with Early Combination Lipid-Lowering Therap... Full story

Yahoo Finance • 2 months ago

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

ANN ARBOR, Mich., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on August 5, 2025, the Company granted 12 new employees 73,500 restricted stock units (RSUs) under Esperion’s 2017 Inducement Equity Incenti... Full story

Yahoo Finance • 2 months ago

Esperion rises after revenue beat, Q1 profitability expectation

[display stock market charts] loveguli/E+ via Getty Images Esperion Therapeutics (NASDAQ:ESPR [https://seekingalpha.com/symbol/ESPR]) shares rose on Tuesday after the company reported second quarter revenue above estimates, and now expect... Full story

Yahoo Finance • 2 months ago

Esperion Therapeutics Inc (NASDAQ:ESPR) Beats Q2 2025 Revenue Forecasts and Reduces Losses Amid Strong Prescription Growth

ESPERION THERAPEUTICS INC (NASDAQ:ESPR [https://www.chartmill.com/stock/quote/ESPR/profile]) SURPASSES REVENUE ESTIMATES, NARROWS LOSSES IN Q2 2025 Esperion Therapeutics Inc (NASDAQ:ESPR [https://www.chartmill.com/stock/quote/ESPR/profile... Full story

Yahoo Finance • 2 months ago

Esperion Reports Second Quarter 2025 Financial Results and Provides Business Update

– Q2 2025 Total Revenue Grew 12% Y/Y to $82.4 Million – – Q2 2025 U.S. Net Product Revenue Grew 42% Y/Y to $40.3 Million – – Total Retail Prescription Equivalents Increased 10% from First Quarter – – Reached Settlement Agreements with T... Full story

Yahoo Finance • 2 months ago

Esperion Therapeutics (ESPR) Gets Boost from Acquisition Rumors

We recently published These 10 Stocks are Winning Big. Esperion Therapeutics, Inc. (NASDAQ:ESPR) is one of the best-performing stocks on Monday. Esperion Therapeutics extended its winning streak to a fifth consecutive day on Monday, addin... Full story

Yahoo Finance • 2 months ago

Esperion to Report Second Quarter 2025 Financial Results on August 5

ANN ARBOR, Mich., July 22, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report second quarter 2025 financial results before the market opens on Tuesday, August 5, 2025. Following the release, management will... Full story

Yahoo Finance • 3 months ago

Esperion Appoints Craig Thompson to Board of Directors

ANN ARBOR, Mich., July 01, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it has appointed Craig Thompson, Chief Executive Officer of Cerevance, to its Board of Directors. Mr. Thompson will serve as an independent direc... Full story

Yahoo Finance • 6 months ago

Esperion to Host R&D Day to Highlight Cardiometabolic Pipeline Innovation and Next-Generation Therapeutics on April 24, 2025

ANN ARBOR, Mich., April 10, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it will host an in-person R&D Day for analysts and investors on April 24, 2025, beginning at 9:00 a.m. ET in New York City. This event will... Full story

Yahoo Finance • 7 months ago

Esperion Reports Fourth Quarter and Full Year 2024 Financial Results

– FY24 Total Revenue Grew 186% Y/Y to $332.3 Million; FY24 U.S. Net Product Revenue Grew 48% Y/Y to $115.7 Million – –Q4 Total Revenue Grew 114% Y/Y to $69.1 Million; Q4 U.S. Net Product Revenue Grew 52% Y/Y to $31.6 Million – – Q4 Retai... Full story

Yahoo Finance • 7 months ago

Esperion Partners with CSL Seqirus to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Australia

ANN ARBOR, Mich., March 03, 2025 (GLOBE NEWSWIRE) -- Esperion Therapeutics (NASDAQ: ESPR) today announced it has entered into a license and distribution agreement with CSL Seqirus (ASX:CSL) for the exclusive rights to commercialize NEXLE... Full story

Yahoo Finance • 7 months ago

Esperion to Report Fourth Quarter and Full Year 2024 Financial Results on March 4

ANN ARBOR, Mich., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report third quarter 2024 financial results before the market opens on Tuesday, March 4, 2025. Following the release, management will ho... Full story

Yahoo Finance • 12 months ago

Is Esperion Therapeutics, Inc. (ESPR) the Best NASDAQ Stock Under $5?

We recently compiled a list of 7 Best NASDAQ Stocks Under $5. In this article, we will look at where Esperion Therapeutics, Inc. (NASDAQ:ESPR) ranks among the best NASDAQ stocks under $5. Job Market Cools Yet Economists Remain Optimistic... Full story

Yahoo Finance • last year

11 Best Low Price Pharma Stocks To Invest In

In this piece, we will take a look at the 13 best low price pharma stocks to invest in. If you want to skip our overview of the pharma industry and want to skip to the five top low price stocks in this list, then you can skip ahead to 5 Be... Full story

Yahoo Finance • 2 years ago

Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including Resolution of Pending Litigation

– Near term payment to Esperion of $100 million plus $25 million in calendar quarter following EMA’s expected decision on Type II(a) variation approval of NILEMDO® (bempedoic acid) Tablet and NUSTENDI® (bempedoic acid and ezetimibe) Tablet... Full story

Yahoo Finance • 2 years ago

U.S. FDA Updates LDL-C Lowering Indication for Esperion’s NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet

Esperion Therapeutics, Inc. – Updated Label Adds Primary Hyperlipidemia, Removes Maximally Tolerated Statin Requirement, Removes Limitation of Use – – Cardiovascular (CV) Risk Reduction Labels Remain on Track: in U.S. with PDUFA Date of... Full story

Yahoo Finance • 2 years ago

Esperion Presents CLEAR Outcomes Analysis of Inflammation as Predictor of Cardiovascular Risk at American Heart Association Scientific Sessions 2023

– A Prespecified, Exploratory Analysis of Participants Reports Those with Higher Baseline Inflammation More Likely to Experience a Major Cardiovascular Event (MACE), Cardiovascular Death, and All-Cause Mortality Compared to Those with the... Full story

Yahoo Finance • 2 years ago

Partners Announce TRANSFORM Trial to Evaluate Personalized Heart Disease Care Strategies at American Heart Association 2023

– Data from Randomized Control Trial Will Advance Evidence for Evaluation and Treatment of Heart Disease by Studying Actual Disease: Atherosclerosis – ANN ARBOR, Mich., Nov. 11, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) announced... Full story